Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
Ericsson H, Sjöberg F, Heijer M, Dorani H, Johansson P, Wollbratt M, Norjavaara E. Ericsson H, et al. Among authors: norjavaara e. Diabetes Res Clin Pract. 2012 Dec;98(3):436-44. doi: 10.1016/j.diabres.2012.09.025. Epub 2012 Sep 23. Diabetes Res Clin Pract. 2012. PMID: 23010558 Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA, Leonsson-Zachrisson M, Ericsson H, Wollbratt M, Knutsson M, Hompesch M, Norjavaara E. Morrow LA, et al. Among authors: norjavaara e. Diabetes Obes Metab. 2012 Dec;14(12):1114-22. doi: 10.1111/j.1463-1326.2012.01661.x. Epub 2012 Jul 31. Diabetes Obes Metab. 2012. PMID: 22775976 Clinical Trial.
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M. Krentz AJ, et al. Among authors: norjavaara e. Diabetes Obes Metab. 2014 Nov;16(11):1096-101. doi: 10.1111/dom.12323. Epub 2014 Jul 3. Diabetes Obes Metab. 2014. PMID: 24909093 Clinical Trial.
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Tamborlane WV, et al. Among authors: norjavaara e. Lancet Diabetes Endocrinol. 2022 May;10(5):341-350. doi: 10.1016/S2213-8587(22)00052-3. Epub 2022 Apr 1. Lancet Diabetes Endocrinol. 2022. PMID: 35378069 Free PMC article. Clinical Trial.
77 results